Suzanne Hendrix is CEO of Pentara Corporation, a boutique CRO in Salt Lake City, Utah, USA specializing in statistics and data management in neurodegenerative diseases. Pentara has supported the study design, data collection and analysis of over 50 clinical trials since 2008. Pentara’s clients include small, medium and large pharmaceutical companies, non-profit groups and academic groups in all phases of development. Pentara has expertise in CDISC standards, statistical genetics, biomarker analysis, Bayesian statistics, machine learning techniques and artificial intelligence. Suzanne received her PhD from Boston University and has over 30 years of clinical trials experience with time spent at CROs and pharmaceutical companies, including projects across many disease areas including respiratory, oncology, reproductive, and cardiovascular. She has been instrumental in analysis and reporting for multiple regulatory submissions including NDAs, PLAs, and ISS/ISE documents. Suzanne has first authored or co-authored over 150 peer-reviewed publications related to both clinical trial results and statistical approaches for clinical trials, most of which relate to analysis and design of trials for neurodegenerative diseases. She has extensive experience in optimally measuring progression over time and identifying outcomes that are likely to be sensitive to effects due to treatments that modify important aspects of the disease.